STOCK TITAN

Notifications

Limited Time Offer! Get Platinum at the Gold price until January 31, 2026!

Sign up now and unlock all premium features at an incredible discount.

Read more on the Pricing page

[Form 4] ZEVRA THERAPEUTICS, INC. Insider Trading Activity

Filing Impact
(Low)
Filing Sentiment
(Positive)
Form Type
4
Rhea-AI Filing Summary

Tamara A. Favorito, a director of ZEVRA THERAPEUTICS, INC. (ZVRA), purchased 3,175 shares of the company's common stock on 09/12/2025 at a reported price of $7.7852 per share. After the transaction, Ms. Favorito beneficially owned 3,894 shares. The Form 4 was executed by Timothy J. Sangiovanni as attorney-in-fact and dated 09/16/2025.

Positive
  • Director purchase disclosed: Tamara A. Favorito acquired 3,175 shares on 09/12/2025 at $7.7852 per share
  • Ownership after transaction provided: Reporting person beneficially owned 3,894 shares following the purchase
  • Form executed and signed: Filing signed by attorney-in-fact Timothy J. Sangiovanni on 09/16/2025
Negative
  • None.

Insights

TL;DR: A company director reported a small open-market purchase of 3,175 shares, increasing her beneficial holdings to 3,894 shares.

This Form 4 documents a non-derivative acquisition by a director of ZVRA on 09/12/2025 at $7.7852 per share. The disclosed holding post-transaction is explicitly 3,894 shares. The filing was signed by an attorney-in-fact on 09/16/2025. The disclosure is routine in nature and contains no additional details about transaction purpose, funding source, or broader changes to insider ownership beyond the single line item reported.

TL;DR: Director-level insider made a disclosed purchase; filing appears complete for the reported transaction.

The Form 4 lists the reporter as a director and indicates a direct acquisition (transaction code P) of 3,175 common shares at $7.7852, resulting in 3,894 shares beneficially owned. The form identifies the reporter's address and the attorney-in-fact signature. No amendments, derivative transactions, or joint filers are reported. The disclosure follows Section 16 reporting requirements for the single non-derivative transaction presented.

SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
1. Name and Address of Reporting Person*
FAVORITO TAMARA A

(Last) (First) (Middle)
C/O ZEVRA THERAPEUTICS, INC.
1180 CELEBRATION BOULEVARD, SUITE 103

(Street)
CELEBRATION FL 34747

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
ZEVRA THERAPEUTICS, INC. [ ZVRA ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director 10% Owner
Officer (give title below) Other (specify below)
3. Date of Earliest Transaction (Month/Day/Year)
09/12/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 09/12/2025 P 3,175 A $7.7852 3,894 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Explanation of Responses:
Remarks:
/s/ Timothy J. Sangiovanni, Attorney-in-Fact for Tamara A. Favorito 09/16/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What transaction did Tamara A. Favorito report on the ZVRA Form 4?

The Form 4 reports a non-derivative purchase of 3,175 common shares on 09/12/2025 at a price of $7.7852 per share.

How many ZVRA shares does the reporting person own after the transaction?

The filing states the reporting person beneficially owned 3,894 shares following the reported transaction.

What is the reporting person's relationship to ZVRA?

The Form 4 identifies the reporting person, Tamara A. Favorito, as a Director of ZEVRA THERAPEUTICS, INC.

When was the Form 4 signed and by whom?

The Form 4 was executed by Timothy J. Sangiovanni, Attorney-in-Fact for Tamara A. Favorito and dated 09/16/2025.

Was this Form 4 filed individually or jointly?

The filing indicates it was filed by one reporting person (Form filed by One Reporting Person is checked).
Zevra Therapeutics Inc

NASDAQ:ZVRA

ZVRA Rankings

ZVRA Latest News

ZVRA Latest SEC Filings

ZVRA Stock Data

529.20M
54.94M
0.69%
65.12%
12.28%
Biotechnology
Pharmaceutical Preparations
Link
United States
CELEBRATION